Navigation Links
New immunotherapy for malignant brain tumors
Date:11/25/2013

This news release is available in German.

Animal experiments show that it is relatively easy to treat cancer in the early stages. However, it is far more difficult to successfully treat advanced cancer. Treatment of brain tumors is particularly challenging because regulatory T-cells accumulate in brain tumors and suppress an immune attack.

In several steps using a new strategy and a novel drug, Burkhard Becher's team from the Institute of Experimental Immunology at the University of Zurich has now succeeded in doing exactly this in the case of glioblastoma, one of the most dangerous brain tumors. First step, they stimulated the body's own immune system in such a way that it recognised and then killed the brain tumor cells even in advanced stages of the disease.

The initial objective of their new study was to break through the tumor's protective shield. "We wanted to establish whether we can actually elicit an immune response to a tumor growing within the brain", explains Burkhard Becher. To this end, the team used the immune messenger substance, Interleukin-12. When Interleukin-12 is produced in the tumor, immune cells are stimulated locally in such a manner that the tumor is attacked and rejected. Once this procedure had worked well in the early stages of the tumor, the researchers waited in the next stage until the tumor was very large and the life expectancy of the untreated test animals was less than three weeks. "We only began treatment when it was, in fact, already too late", says the first author of the study Johannes vom Berg. The success rate was low, Berg adds. "We then injected biopharmaceutical Interleukin-12 into the large brain tumor. This did induce an immune response but only led to tumor rejection in one-quarter of the animals."

From 25 to 80 percent: combined treatment leads to success

The researchers were successful when they drew on a new development in skin cancer treatment. They combined intra-tumoral Interleukin-12 treatment with the intravenous administration of a novel immunostimulating drug that suppresses the regulatory T-cells. The rejection of the tumor then worked in 80 percent of the test animals. "I have rarely seen such convincing data in preclinical glioma treatment", says Michael Weller, neurooncologist and Director of the Clinic for Neurology at the University Hospital Zurich. He added, "That's why this development should be tested as soon as possible in clinical trials."

In a joint trial, the team then tested the treatment in a further tumor model which mimics the clinical situation of the brain tumor patient even better. And once again they were successful.

The next step: a clinical trial as soon as possible

The findings of the current research work have been published in the Journal of Experimental Medicine. Their promising results do not mean that the treatment can already be as effective in brain tumor patients. This has to be examined in the next phase for which the team now actively seek commercial partners. Burkhard Becher puts it like this, "We are cautiously optimistic but it's time that we adopted completely new strategies to really get to grips with this fatal tumor"


'/>"/>

Contact: Burkhard Becher, Ph.D.
becher@immunology.uzh.ch
41-446-353-703
University of Zurich
Source:Eurekalert

Related medicine news :

1. Immunotherapy for elderly cancer patients finds new promise in drug combination
2. Antibodies reverse type 1 diabetes in new immunotherapy study
3. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
4. Sublingual immunotherapy shows promise as treatment for peanut allergy
5. Immunotherapy reduces allergic patients sensitivity to peanuts
6. 2-step immunotherapy attacks advanced ovarian cancer
7. Study by Allegheny General Hospital Physicians Shows Oral Immunotherapy is a Safe, Effective Alternative to Allergy Shots for Ragweed Sufferers
8. Researchers to develop next generation immunotherapy for children with deadly solid tumors
9. 2-step ovarian cancer immunotherapy made from patients own tumor shows promise
10. Cancer Research Institute Announces June Cancer Immunotherapy Awareness Month; 1-800-FLOWERS.COM® and The Fund for Park Avenue to Support and Promote Awareness
11. Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology: